Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Published:2015-09-08 Issue:12 Volume:16 Page:1071-1080
ISSN:1467-7881
Container-title:Obesity Reviews
language:en
Short-container-title:Obes Rev

Author:

Aldekhail N. M.¹,Logue J.¹,McLoone P.²,Morrison D. S.²

Affiliation:

1. Institute of Cardiovascular and Medical Sciences; University of Glasgow; Glasgow UK

2. West of Scotland Cancer Surveillance Unit; Institute of Health and Wellbeing; University of Glasgow; Glasgow UK

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/obr.12318/fullpdf

Reference31 articles.

1. World Health Organization Obesity and overweight 2014 http://www.who.int/mediacentre/factsheets/fs311/en/index.html

2. A systematic review of the impact of weight loss on cancer incidence and mortality;Birks;Obes Rev,2012

3. World Health Organization Diabetes 2014 http://www.who.int/mediacentre/factsheets/fs312/en/index.html

4. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial;Davidson;JAMA,1999

5. Standards of medical care for patients with diabetes mellitus;American Diabetes A.;Diabetes Care,2003

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes;Diabetes Therapy;2024-09-14

2. Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial;Lipids in Health and Disease;2024-07-24

3. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database;Heliyon;2024-07

4. Obesity medications: A narrative review of current and emerging agents;Osteoarthritis and Cartilage Open;2024-06

5. The cardiovascular effects of novel weight loss therapies;European Heart Journal;2023-11-15